Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC

Eye & ENT Hospital of Fudan University

Status and phase

Enrolling

Phase 2

Conditions

Recurrent Nasopharyngeal Carcinoma

Treatments

Procedure: endoscopic surgery

Study type

Interventional

Funder types

Other

Identifiers

NCT05350891

rNPC-SA-Ad-Immuno-V1

Details and patient eligibility

About

A Prospective, Single-arm, Multicenter Clinical Study of Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent Nasopharyngeal Carcinoma

Enrollment

77 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Pathology or radiography confirmed recurrent nasopharyngeal carcinoma.
AJCC rT1-T4 which can be surgically removed.
Age ≥18 years old.
Informed consent signed.
With or without lymph node metastasis, which can be surgically removed.
No distant metastasis.
≥6 months from the end of initial radiotherapy to recurrence.
Sufficient organ function a)Hematology: white blood cells ≥3.0 x 109/L, absolute neutrophil count ≥1.5x 109/L, hemoglobin ≥80 g/L, platelets ≥100 x 109/L. b) Liver function: bilirubin ≤ 1.5 times the upper limit of normal (ULN), AST and ALT ≤ 3 times the ULN c) International normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN. d) Renal function: serum creatinine ≤ 1.5 times ULN.
ECOG score 0-2. general physical condition can tolerate general anesthesia surgery, chemotherapy, and immunotherapy.

Exclusion criteria

Evidence of distant metastasis or leptomeningel disease (LMD).
Have received radioactive seed implantation in the treatment area.
Suffer from uncontrolled disease which could interfere with treatment.
Suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.).
The patient has surgical contraindications: such as severe cardiopulmonary disease, coagulation dysfunction and so on.
The patients have autoimmune diseases.
The patient is using immunosuppressive agents or systemic glucocorticoid to achieve the purpose of immunosuppression (dose>10mg/day prednisone or other), and continues to use it within 2 weeks before the first administration.
Severe allergic reaction to other monoclonal antibodies.
Previously received PD-1 monoclonal antibody, CTLA-4 monoclonal antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway) treatment.
Live vaccines have been inoculated within 4 weeks before the first administration or during the study period.
The patient has any situation that may hinder study compliance or the safety during the study period.
Existence of serious neurological or psychiatric diseases, such as dementia and seizures.
Uncontrolled active infection.
Pregnant or breastfeeding women.
Those who have no personal freedom and independent capacity for civil conduct.
There are other situations that are not suitable for entry into the study.